TherapeuticsMD (TXMD) 10-Q 7 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	4-May-15
Document And Entity Information
Entity Registrant Name	TherapeuticsMD, Inc.
Entity Central Index Key	25743
Document Type	10-Q
Document Period End Date	31-Mar-15
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		172,656,036
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2015

CONSOLIDATED_BALANCE_SHEETS_Un

CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current Assets:
Cash	$91,658,453	$51,361,607
Accounts receivable, net of allowance for doubtful accounts of $72,757 and $59,753, respectively	2,644,049	2,154,217
Inventory	959,188	1,182,113
Other current assets	1,445,995	1,537,407
Total current assets	96,707,685	56,235,344
Fixed assets, net	56,412	63,293
Other Assets:
Prepaid expense	1,334,139	1,427,263
Intangible assets	1,258,750	1,228,588
Security deposit	125,000	125,000
Total other assets	2,717,889	2,780,851
Total assets	99,481,986	59,079,488
Current Liabilities:
Accounts payable	6,235,183	6,327,129
Other current liabilities	4,879,452	3,840,639
Deferred revenue		522,613
Total current liabilities	11,114,635	10,690,381
Long-Term Liabilities:
Accrued Expense	651,567
Total liabilities	11,766,202	10,690,381
Commitments and Contingencies
Stockholders' Equity:
Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding
Common stock - par value $0.001; 250,000,000 shares authorized; 172,651,036 and 156,097,019 issued and outstanding, respectively	172,651	156,097
Additional paid in capital	243,187,225	182,982,846
Accumulated deficit	-155,644,092	-134,749,836
Total stockholders' equity	87,715,784	48,389,107
Total liabilities and stockholders' equity	$99,481,986	$59,079,488

CONSOLIDATED_BALANCE_SHEETS_Un1

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$72,757	$59,753
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	172,651,036	156,097,019
Common stock, shares outstanding	172,651,036	156,097,019

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Revenues, net	$4,475,049	$2,830,533
Cost of goods sold	1,043,641	830,707
Gross profit	3,431,408	1,999,826
Operating expenses:
Sales, general, and administrative	6,163,612	5,029,497
Research and development	18,176,835	5,908,078
Depreciation and amortization	13,572	13,068
Total operating expense	24,354,019	10,950,643
Operating loss	-20,922,611	-8,950,817
Other income and (expense)
Miscellaneous income	18,513	18,572
Interest income	9,842	9,154
Financing costs		-260,027
Total other income (expense)	28,355	-232,301
Loss before taxes	-20,894,256	-9,183,118
Provision for income taxes
Net loss	($20,894,256)	($9,183,118)
Net loss per share, basic and diluted (in dollars per share)	($0.13)	($0.06)
Weighted average number of common shares outstanding-basic and diluted (in shares)	163,448,130	145,019,561

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	($20,894,256)	($9,183,118)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation	6,881	7,122
Amortization of intangible assets	6,691	5,946
Provision for doubtful accounts	13,004	6,046
Stock based compensation	704,872	1,009,526
Amortization of deferred financing costs		260,027
Stock based expense for services	135,592	314,291
Changes in operating assets and liabilities:
Accounts receivable	-502,836	-654,748
Inventory	222,925	122,933
Other current assets	91,412	-85,834
Other assets	-9,842	-9,154
Accounts payable	-91,946	954,513
Deferred revenue	-522,613	-124,271
Accrued expenses and other current liabilities	1,038,813	-1,329,216
Other long-term liabilities	651,567
Net cash flows used in operating activities	-19,149,736	-8,705,937
CASH FLOWS FROM INVESTING ACTIVITIES
Patent costs	-36,853	-97,284
Purchase of property and equipment		-23,692
Net cash flows used in investing activities	-36,853	-120,976
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of common stock, net of costs	59,117,827
Proceeds from exercise of options	7,208	40,055
Proceeds from exercise of warrants	358,400
Net cash flows provided by financing activities	59,483,435	40,055
Increase (decrease) in cash	40,296,846	-8,786,858
Cash, beginning of period	51,361,607	54,191,260
Cash, end of period	$91,658,453	$45,404,402

THE_COMPANY

THE COMPANY	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
THE COMPANY	NOTE 1 – THE COMPANY
	TherapeuticsMD, Inc., a Nevada corporation, or TherapeuticsMD or the Company, has two wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed, and BocaGreenMD, Inc., a Nevada corporation, or BocaGreen. Unless the context otherwise requires, TherapeuticsMD, VitaMed, and BocaGreen collectively are sometimes referred to as “our company,” “we,” “our,” or “us.”
	Nature of Business
	We are a women’s health care product company focused on creating and commercializing products targeted exclusively for women. As of the date of these consolidated financial statements, we are focused on conducting the clinical trials necessary for regulatory approval and commercialization of our advanced hormone therapy pharmaceutical products. The drug candidates used in our clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and vaginal discomfort. We are developing these hormone therapy drug candidates, which contain estradiol and progesterone alone or in combination, with the aim of demonstrating equivalent clinical efficacy at lower doses, thereby enabling an enhanced side effect profile compared with competing products. Our drug candidates are created from a platform of hormone technology that enables the administration of hormones with high bioavailability alone or in combination. In addition, we manufacture and distribute branded and generic prescription prenatal vitamins, as well as over-the-counter, or OTC, vitamins.

BASIS_OF_PRESENTATION_AND_RECE

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS	NOTE 2 – BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
	Interim Financial Statements
	The accompanying unaudited interim consolidated financial statements of TherapeuticsMD, Inc., which include our wholly owned subsidiaries, should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2014, as filed with the Securities and Exchange Commission, or the SEC, from which we derived our balance sheet as of December 31, 2014. The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, since they are interim statements, the accompanying unaudited interim consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements. The accompanying unaudited interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of our management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year.
	In August 2014, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, No. 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. ASU 2014-15 requires management to evaluate whether there are conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the financial statements are issued (or available to be issued when applicable) and, if so, disclose that fact. ASU 2014-15 is effective for annual periods ending after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. We do not expect the adoption of the ASU 2014-15 to have a material effect on our consolidated financial statements and disclosures.
	In May 2014, the FASB and the International Accounting Standards Board (IASB) issued ASU, No. 2014-09, Revenue from Contracts with Customers (Topic 606). The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under previous guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligations. ASU 2014-09 is effective for public business entities, certain not-for-profit entities and certain employee benefit plans, for annual periods beginning after December 15, 2016, including interim periods within that period. Early adoption is not permitted under GAAP. We are currently evaluating the impact of ASU 2014-09 on our consolidated financial statements and disclosures.
	We do not believe there would have been a material effect on the accompanying consolidated financial statements had any other recently issued, but not yet effective, accounting standards been adopted in the current period.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Impairment of Long-Lived Assets
	We review the carrying values of property and equipment and long-lived intangible assets for impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. Such events or circumstances include the following:
		·	significant declines in an asset’s market price;
		·	significant deterioration in an asset’s physical condition;
		·	significant changes in the nature or extent of an asset’s use or operation;
		·	significant adverse changes in the business climate that could impact an asset’s value, including adverse actions or assessments by regulators;
		·	accumulation of costs significantly in excess of original expectations related to the acquisition or construction of an asset;
		·	current-period operating or cash flow losses combined with a history of such losses or a forecast that demonstrates continuing losses associated with an asset’s use; and
		·	expectations that it is more likely than not that an asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.
	If impairment indicators are present, we determine whether an impairment loss should be recognized by testing the applicable asset or asset group’s carrying value for recoverability. This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted future cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used. In our assessments, we also consider changes in asset utilization, including the temporary idling of capacity and the expected timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then we record a loss for the difference between the assets’ fair value and respective carrying values. We determine the fair value of the assets using an “income approach” based upon a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant estimates and assumptions include market size and growth, market share, projected selling prices, manufacturing cost, and discount rate. We base estimates upon historical experience, our commercial relationships, market conditions, and available external information about future trends. We believe our current assumptions and estimates are reasonable and appropriate. Unanticipated events and changes in market conditions, however, could affect such estimates, resulting in the need for an impairment charge in future periods. There was no impairment of intangibles or long-lived assets during the three months ended March 31, 2015 and 2014.
	Fair Value of Financial Instruments
	Our financial instruments consist primarily of accounts receivable, accounts payable and accrued expenses. The carrying amount of accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments.
	We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by Accounting Standards Codification, or ASC, 820, Fair Value Measurements. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:
		Level 1	unadjusted quoted prices in active markets for identical assets or liabilities;
		Level 2	quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and
		Level 3	unobservable inputs for the asset or liability.
	At March 31, 2015 and 2014, we had no assets or liabilities that were valued at fair value on a recurring basis.
	The fair value of indefinite-lived assets or long-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with the Company’s impairment test. There was no impairment of intangible assets or long-lived assets during the three months ended March 31, 2015 and 2014.
	Revenue Recognition
	We recognize revenue on arrangements in accordance with ASC 605, Revenue Recognition. We recognize revenue only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably assured.
	Our OTC and prescription prenatal vitamin products are generally variations of the same product with slight modifications in formulation and marketing. The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers of our OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products pay for the product via third-party payers. Both OTC and prescription prenatal vitamin products share the same marketing support team utilizing similar marketing techniques.
	Over-the-Counter Products
	We generate OTC revenue from product sales primarily to retail consumers. We recognize revenue from product sales upon shipment, when the rights of ownership and risk of loss have passed to the consumer. We include outbound shipping and handling fees in sales and bill them upon shipment. We include shipping expenses in cost of sales. A majority of our customers pay for our products with credit cards, and we usually receive the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to sales. We provide an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce customers. We recognize our revenue from OTC sales, net of returns, sales discounts, and eCommerce fees.
	Prescription Products
	We sell our name brand and generic prescription products primarily through drug wholesalers and retail pharmacies. We recognize revenue from prescription product sales, net of sales discounts, chargebacks, and rebates.
	We accept returns of unsalable product from customers within a return period of six months prior to and up to 12 months following product expiration. Our prescription products currently have a shelf life of 24 months from the date of manufacture. As of January 1, 2015, we started estimating returns based on historical return rates and record actual product returns against this reserve as received.
	We maintain various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. The consumer rebate program is designed to enable the end user to return a coupon to us. If the coupon qualifies, we send a rebate check to the end user. We estimate the allowance for consumer rebates based on our experience and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis.
	Research and Development Expenses
	Research and development, or R&D, expenses include internal R&D activities, services of external contract research organizations, or CROs, costs of their clinical research sites, and other activities. Internal R&D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. Advance payments to be expensed in future research and development activities were $995,144 and $1,175,082, at March 31, 2015 and December 31, 2014, respectively. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting and legal counsel. The activities undertaken by our regulatory consultants that were classified as research and development expenses include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. Legal activities that were classified as research and development expenses related to designing experiments to generate data for patents and to further the formulation development process for our pipeline technologies. Outside legal counsel also provided professional research regarding the legal landscape of potential patents. These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal R&D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&D activities when the activity has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. As of March 31, 2015, we classified $651,567 of the accrued clinical study costs as Accrued Expense related to the costs that will be paid at the completion of one of our clinical trials. Accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become known.
	Segment Reporting
	We are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by a single management team that reports to the President of our Company. We do not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.

INVENTORY

INVENTORY	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
INVENTORY	NOTE 4 – INVENTORY
	Inventory consists of the following:
		March 31,   2015		December 31,   2014
	Finished product	$	789,174	$	874,294
	Raw material		170,014		155,341
	Deferred costs		—		152,478
	TOTAL INVENTORY	$	959,188	$	1,182,113

OTHER_CURRENT_ASSETS

OTHER CURRENT ASSETS	3 Months Ended
	Mar. 31, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
OTHER CURRENT ASSETS	NOTE 5 – OTHER CURRENT ASSETS
	Other current assets consist of the following:
		March 31,   2015		December 31,   2014
	Prepaid consulting	$	411,864	$	411,864
	Other receivables-related party (Note 13)		249,981		249,981
	Prepaid insurance		237,867		394,878
	Prepaid research and development costs		222,526		299,498
	Prepaid vendor deposits		171,374		—
	Other prepaid costs		152,383		181,186
	TOTAL OTHER CURRENT ASSETS	$	1,445,995	$	1,537,407

FIXED_ASSETS

FIXED ASSETS	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
FIXED ASSETS	NOTE 6 – FIXED ASSETS
	Fixed assets consist of the following:
		March 31,   2015			31-Dec-14
	Equipment	$	132,150		$	132,150
	Furniture and fixtures		53,895			53,895
			186,045			186,045
	Accumulated depreciation		(129,633	)		(122,752	)
	TOTAL FIXED ASSETS	$	56,412		$	63,293
	Depreciation expense for the three months ended March 31, 2015 and 2014 was $6,881 and $7,122 respectively.

PREPAID_EXPENSE

PREPAID EXPENSE	3 Months Ended
	Mar. 31, 2015
Prepaid Expense and Other Assets [Abstract]
PREPAID EXPENSE	NOTE 7 – PREPAID EXPENSE
	Prepaid expense consists of the following:
		March 31,   2015		31-Dec-14
	Prepaid manufacturing costs	$	899,000	$	899,000
	Prepaid research and development costs		360,754		463,720
	Accreted prepaid costs		74,385		64,543
	TOTAL PREPAID EXPENSE	$	1,334,139	$	1,427,263

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 8 – INTANGIBLE ASSETS
	The following table sets forth the gross carrying amount and accumulated amortization of our intangible assets as of March 31, 2015 and December 31, 2014:
			31-Mar-15
			Gross Carrying Amount				Accumulated Amortization			Net		Weighted- Average Amortization Period (yrs.)
										Amount
	Amortizing intangible assets:
	OPERA® software patent		$	31,951			$	(2,995	)	$	28,956		14.5
	Development costs of corporate website			91,743				(91,743	)		—		n/a
	Approved hormone therapy drug candidate patents			439,184				(25,593	)		413,591		17.75
	Non-amortizing intangible assets:
	Hormone therapy drug candidate patents (pending)			691,465				—			691,465		n/a
	Multiple trademarks for vitamins/supplements			124,738				—			124,738		n/a
	Total		$	1,379,081			$	(120,331	)	$	1,258,750
			31-Dec-14
			Gross Carrying Amount				Accumulated Amortization			Net		Weighted- Average Amortization Period (yrs.)
										Amount
	Amortizing intangible assets:
	OPERA® software patent		$	31,951			$	(2,496	)	$	29,455		14.75
	Development costs of corporate website			91,743				(91,743	)		—		n/a
	Approved hormone therapy drug candidate patents			439,184				(19,401	)		419,783		18
	Non-amortizing intangible assets:
	Hormone therapy drug candidate patents (pending)			675,982				—			675,982		n/a
	Multiple trademarks for vitamins/supplements			103,368				—			103,368		n/a
	Total		$	1,342,228			$	(113,640	)	$	1,228,588
	We amortize the intangible asset related to development costs for corporate website over 36 months, which is the prescribed life for software and website development costs. The average enforceable life of patents is 20 years. We amortize the intangible asset related to OPERA® using the straight-line method over the estimated remaining useful life of approximately 15 years. We amortize the approved hormone therapy drug candidate patents using straight-line method over the estimated remaining useful life of approximately 18 years. During the three months ended March 31, 2015 and 2014, there was no impairment recognized.
	In addition to numerous pending patent applications, as of March 31, 2015, we had nine issued patents, including:
		•	one method patent that relates to our OPERA® information technology platform, which is owned by us and is a U.S. jurisdiction patent with an expiration date in 2029;
		•	eight utility patents that relate to our combination progesterone and estradiol formulations, which are owned by us and are U.S. jurisdiction patents with expiration dates in 2032. We have pending patent applications with respect to certain of these patents in Argentina, Australia, Canada, the European Union, Israel, Mexico, Brazil, Japan, Russia, South Africa and South Korea.
	Subsequent to March 31, 2015, two additional patents were issued related to our combination progesterone and estradiol formulations.
	Amortization expense was $6,691 and $5,946 for the three months ended March 31, 2015 and 2014, respectively. Estimated amortization expense for the next five years is as follows:
	Year Ending				Estimated
	December 31,				Amortization
		2015 (9 months)			$	20,074
		2016			$	26,765
		2017			$	26,765
		2018			$	26,765
		2019			$	26,765

OTHER_CURRENT_LIABILITIES

OTHER CURRENT LIABILITIES	3 Months Ended
	Mar. 31, 2015
Other Liabilities Disclosure [Abstract]
OTHER CURRENT LIABILITIES	NOTE 9 – OTHER CURRENT LIABILITIES
	Other current liabilities consist of the following:
			March 31,   2015		31-Dec-14
	Accrued clinical trial costs		$	2,672,962	$	1,706,542
	Accrued payroll, bonuses and commission costs			900,662		814,205
	Accrued vacation costs			429,740		442,430
	Accrued legal and accounting expense			114,760		276,470
	Other accrued expenses(1)			312,181		185,965
	Allowance for wholesale distributor fees			121,469		160,503
	Accrued royalties			53,415		72,710
	Allowance for coupons and returns			184,521		90,446
	Accrued rent			89,742		91,368
	TOTAL OTHER CURRENT LIABILITIES		$	4,879,452	$	3,840,639
	____________
	-1	In June 2008, we declared and paid a special dividend of $0.40 per share of our Common Stock to all stockholders of record as of June 10, 2008, of which $41,359 remained unclaimed by certain shareholders at March 31, 2015 and December 31, 2014.

NET_LOSS_PER_SHARE

NET LOSS PER SHARE	3 Months Ended
	Mar. 31, 2015
Net Loss Per Share
NET LOSS PER SHARE	NOTE 10 – NET LOSS PER SHARE
	We calculate basic and diluted net loss per share allocable to common stockholders using the weighted-average number of shares of common stock, par value $0.001 per share, or Common Stock outstanding during the period, less any shares subject to repurchase or forfeiture. There were no shares of our Common Stock outstanding subject to repurchase or forfeiture for the three months ended March 31, 2015 and 2014.
	Since we are in a net loss position, we have excluded outstanding stock options and restricted stock units, all of which are subject to forfeiture, as well as warrants for the purchase of our Common Stock from our calculation of diluted net loss per share.
	The table below presents the potentially dilutive securities that would have been included in our calculation of diluted net loss per share allocable to common stockholders if they were not antidilutive for the periods presented.
		Three months ended
		31-Mar-15		31-Mar-14
	Stock options		17,586,109		16,511,006
	Warrants		13,002,431		14,293,499
	Restricted stock units		—		50,000
			30,588,540		30,854,505

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity:
STOCKHOLDERS' EQUITY	NOTE 11 – STOCKHOLDERS’ EQUITY
	Preferred Stock
	At March 31, 2015, we had 10,000,000 shares of Preferred Stock, par value $0.001, authorized for issuance, of which no shares of Preferred Stock were issued or outstanding.
	Common Stock
	At March 31, 2015, we had 250,000,000 shares of Common Stock authorized, of which 172,651,036 shares of Common Stock were issued and outstanding.
	On February 10, 2015, we entered into an underwriting agreement, or the Cowen Agreement, with Cowen and Company, LLC, as the representative of the several underwriters, or the Cowen Underwriters, relating to an underwritten public offering of 13,580,246 shares of Common Stock, at a public offering price of $4.05 per share. Under the terms of the Cowen Agreement, we granted the Cowen Underwriters a 30-day option to purchase up to an aggregate of 2,037,036 additional shares of Common Stock, which option was exercised in full. The net proceeds from the offering were approximately $59,100,000, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on February 17, 2015.
	During the three months ended March 31, 2015, a certain individual exercised stock options to purchase 11,250 shares of Common Stock for $7,208 in cash. During the three months ended March 31, 2015, an outside service provider exercised warrants to purchase 925,485 of our Common Stock for $358,400 in cash.
	During the three months ended March 31, 2014, certain individuals exercised stock options to purchase 90,303 shares of Common Stock. Stock options to purchase shares of Common Stock were exercised as follows: (1) 88,736 shares for $40,055 in cash and (ii) 1,567 shares, pursuant to the stock options’ cashless provision, wherein 1,433 shares were cancelled.
	Warrants to Purchase Common Stock
	As of March 31, 2015, we had warrants outstanding to purchase an aggregate of 13,002,431 shares of Common Stock with a weighted-average contractual remaining life of 2.5 years, and exercise prices ranging from $0.24 to $3.20 per share, resulting in a weighted average exercise price of $1.92 per share.
	The valuation methodology used to determine the fair value of our warrants is the Black-Scholes-Merton valuation model, or the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate and the term of the warrant.
	In January 2013, we granted warrants to purchase 1,250,000 shares of Common Stock in connection with the issuance of a Revolving Credit Note to Plato and Associates, LLC, or the Plato Warrant. The Plato Warrant has an exercise price of $3.20 per share. The Plato Warrant vested on October 31, 2013 and may be exercised prior to its expiration on January 31, 2019. The Plato Warrant, with a fair value of $1,711,956, was valued on the date of the grant using a term of six years; a volatility of 44.29%; risk free rate of 0.88%; and a dividend yield of 0%. For the three months ended March 31, 2015 and 2014, $0 and $260,027, respectively, was recorded as financing costs in connection with the issuance of the Plato Warrant on the accompanying consolidated financial statements.
	In May 2013, we entered into a consulting agreement with Sancilio & Company, Inc., or SCI, to develop drug platforms to be used in our hormone replacement drug candidates. These services include support of our efforts to successfully obtain U.S. Food and Drug Administration, or the FDA, approval for our drug candidates, including a vaginal capsule for the treatment of vulvar and vaginal atrophy, or VVA. In connection with the agreement, SCI agreed to forfeit its rights to receive warrants to purchase 833,000 shares of Common Stock that were to be granted pursuant to the terms of a prior consulting agreement dated May 17, 2012. As consideration under the agreement, we agreed to grant to SCI a warrant to purchase 850,000 shares of Common Stock at $2.01 per share that has vested or will vest, as applicable, as follows:
		1	283,333 shares were earned on May 11, 2013 upon acceptance of an Investigational New Drug application by the FDA for an estradiol-based drug candidate in a softgel vaginal capsule for the treatment of VVA; however, pursuant to the terms of the consulting agreement, the shares did not vest until June 30, 2013. The fair value of $405,066 for the shares vested on June 30, 2013 was determined by using the Black-Scholes Model on the date of vesting using a term of five years; a volatility of 45.89%; risk free rate of 1.12%; and a dividend yield of 0%. We recorded the entire $405,066 as non-cash compensation as of June 30, 2013;
		2	283,333 shares vested on June 30, 2013. The fair value of $462,196 for these shares was determined by using the Black-Scholes Model on the date of the vesting using a term of five years; a volatility of 45.84%; risk free rate of 1.41%; and a dividend yield of 0%. We recorded $154,068 as prepaid expense-short term and $38,509 as prepaid expense-long term in the accompanying consolidated financial statements. During both three months ended March 31, 2015 and 2014, we recorded $38,517 as non-cash compensation in the accompanying consolidated financial statements; and
		3	283,334 shares will vest upon the receipt by us of any final FDA approval of a drug candidate that SCI helped us design. It is anticipated that this event will not occur before December 2015.
	During the three months ended March 31, 2015 and 2014, we did not grant any warrants. As of March 31, 2015, unamortized costs associated with the SCI warrants issued in 2013 and 2012 totaled approximately $773,000.
	Options to Purchase Common Stock
	In 2009, we adopted the 2009 Long Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created stockholder value by providing them stock options and other stock and cash incentives, or the Awards. The Awards available under the 2009 Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described in the 2009 Plan. There are 25,000,000 shares authorized for issuance thereunder. As of March 31, 2015, there were non-qualified stock options to purchase 15,617,635 shares of Common Stock outstanding under the 2009 Plan.
	In 2012, we adopted the 2012 Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company. There are 10,000,000 shares of Common Stock authorized for issuance thereunder. As of March 31, 2015, there were non-qualified stock options to purchase 1,968,474 shares of Common Stock outstanding under the 2012 Plan.
	The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The assumptions used in the Black-Scholes Model during the three months ended March 31, 2015 and 2014 are set forth in the table below.
			Three Months			Three Months
			Ended			Ended
			March 31,			March 31,
			2015			2014
	Risk-free interest rate			1.47	%		1.70-1.75	%
	Volatility			58.78-62.59	%		69.15-70.76	%
	Term (in years)			5.27-6.25			5.5-6.25
	Dividend yield			0	%		0	%
	The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected term. Estimated volatility is a measure of the amount by which the price of our Common Stock is expected to fluctuate each year during the term of an award. Our estimated volatility is an average of the historical volatility of the stock prices of our peer entities whose stock prices were publicly available. Our calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards. We used the historical volatility of our peer entities due to the lack of sufficient historical data on our stock price. The average expected life is based on the contractual terms of the stock option using the simplified method.
	A summary of activity under the 2009 and 2012 Plans and related information follows:
			Number of Shares Underlying Stock			Weighted Average Exercise Price			Weighted   Average   Remaining   Contractual Life in Years		Aggregate Intrinsic Value
			Options
	Balance at December 31, 2014			16,792,443		$	1.88			6.92	$	43,996,311
	Granted			919,500		$	5.92
	Exercised			(11,250	)	$	0.64
	Cancelled			(114,584	)	$	2.82
	Balance at March 31, 2015			17,586,109		$	2.09			6.53	$	69,714,593
	Vested and Exercisable at			13,701,873		$	1.5			5.89	$	62,312,047
	31-Mar-15
	At March 31, 2015, our outstanding stock options had exercise prices ranging from $0.10 to $5.92 per share.
	Share-based compensation expense for options recognized in our results for the three months ended March 31, 2015 and 2014 ($728,426 and $1,006,025, respectively) is based on vested awards. ASC 718-10 requires forfeitures to be estimated at the time of grant and revised in subsequent periods if actual forfeitures differ from the estimates. At March 31, 2015, total unrecognized estimated compensation expense related to unvested options granted prior to that date was approximately $7,209,000 which may be adjusted for future changes in forfeitures. This cost is expected to be recognized over a weighted-average period of 2.1 years. No tax benefit was realized due to a continued pattern of operating losses.

INCOME_TAXES

INCOME TAXES	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 12 – INCOME TAXES
	Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We do not expect to pay any significant federal or state income tax for 2015 as a result of (i) the losses recorded during the three months ended March 31, 2015, (ii) additional losses expected for the remainder of 2015, and/or (iii) net operating loss carry forwards from prior years. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is “more likely than not” that some component or all of the benefits of deferred tax assets will not be realized. As of March 31, 2015, we maintain a full valuation allowance for all deferred tax assets. Based on these requirements, no provision or benefit for income taxes has been recorded. There were no recorded unrecognized tax benefits at the end of the reporting period.

RELATED_PARTIES

RELATED PARTIES	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
RELATED PARTIES	NOTE 13 – RELATED PARTIES
	On February 29, 2012, Cooper C. Collins, who was then president and largest shareholder of Pernix Therapeutics, LLC, or Pernix, was elected to serve on our board of directors. From time to time, we have entered into agreements with Pernix in the normal course of business. All such agreements are reviewed by independent directors of our company or a committee consisting of independent directors of our company. During the three months ended March 31, 2015 and 2014, we did not engage in any transactions with Pernix. At March 31, 2015 and December 31, 2014, there were amounts due Pernix of approximately $46,000.
	Additionally, there were amounts due to us from Pernix for legal fee reimbursement relating to a litigation matter stemming from a license and supply agreement in the amounts of $249,981 at both March 31, 2015 and December 31, 2014.

BUSINESS_CONCENTRATIONS

BUSINESS CONCENTRATIONS	3 Months Ended
	Mar. 31, 2015
Risks and Uncertainties [Abstract]
BUSINESS CONCENTRATIONS	NOTE 14 – BUSINESS CONCENTRATIONS
	We purchase our products from several suppliers with approximately 95% and 84% of our purchases supplied from one vendor for the three months ended March 31, 2015 and 2014, respectively.
	We sell our prescription prenatal vitamin products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. Revenue generated from four major customers accounted for approximately 70.40% and 81.75% of our recognized revenue for the three months ended March 31, 2015 and 2014, respectively.
	We had four customers that generated more than 10% of our sales for the three months ended March 31, 2015 and three customers that generated more than 10% of our sales for the three months ended March 31, 2014 – these customers are designated as customers “A”, “B”, “C” and “D”. Customers A, B, C and D generated $1,416,127, $626,731, $543,447 and $386,909 in sales, respectively for the three months ended March 31, 2015 and $918,018, $0, $585,376 and $562,484 in sales, respectively, for the three months ended March 31, 2014.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 15 – COMMITMENTS AND CONTINGENCIES
	We lease administrative office space in Boca Raton, Florida pursuant to a 63 month non-cancelable operating lease that commenced on July 1, 2013 and expires on September 30, 2018. The lease stipulates, among other things, average base monthly rents of $30,149 (inclusive of estimated operating expenses) and sales tax, for a total future minimum payments over the life of the lease of $1,899,414.
	On February 18, 2015, we entered into an agreement to lease additional administrative office space in Boca Raton, Florida, pursuant to an addendum to such lease. This addendum is effective beginning April 1, 2015 and will expire with the original lease term on September 30, 2018. The lease addendum stipulates, among other things, average base monthly rents of $9,367 (inclusive of estimated operating expenses) and sales tax, for a total future minimum payments over the life of the lease of $393,429.
	The straight line rental expense related to our current lease totaled $90,448 for each of the three months ended March 31, 2015 and 2014, partially offset by the rent income of $0 and $17,980, respectively, for sublet space.
	As of March 31, 2015, future minimum rental payments are as follows:
	Years Ending December 31,
		2015 (9 months)	$	362,350
		2016		493,790
		2017		507,087
		2018		388,976
		Total minimum lease payments		1,752,203
		Non-cancellable sub-lease income		(—)
		Net minimum lease payments	$	1,752,203

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets
	We review the carrying values of property and equipment and long-lived intangible assets for impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. Such events or circumstances include the following:
		•	significant declines in an asset’s market price;
		•	significant deterioration in an asset’s physical condition;
		•	significant changes in the nature or extent of an asset’s use or operation;
		•	significant adverse changes in the business climate that could impact an asset’s value, including adverse actions or assessments by regulators;
		•	accumulation of costs significantly in excess of original expectations related to the acquisition or construction of an asset;
		•	current-period operating or cash flow losses combined with a history of such losses or a forecast that demonstrates continuing losses associated with an asset’s use; and
		•	expectations that it is more likely than not that an asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.
	If impairment indicators are present, we determine whether an impairment loss should be recognized by testing the applicable asset or asset group’s carrying value for recoverability. This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted future cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used. In our assessments, we also consider changes in asset utilization, including the temporary idling of capacity and the expected timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then we record a loss for the difference between the assets’ fair value and respective carrying values. We determine the fair value of the assets using an “income approach” based upon a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant estimates and assumptions include market size and growth, market share, projected selling prices, manufacturing cost, and discount rate. We base estimates upon historical experience, our commercial relationships, market conditions, and available external information about future trends. We believe our current assumptions and estimates are reasonable and appropriate. Unanticipated events and changes in market conditions, however, could affect such estimates, resulting in the need for an impairment charge in future periods. There was no impairment of intangibles or long-lived assets during the three months ended March 31, 2015 and 2014.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	Our financial instruments consist primarily of accounts receivable, accounts payable and accrued expenses. The carrying amount of accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments.
	We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by Accounting Standards Codification, or ASC, 820, Fair Value Measurements. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:
		Level 1	unadjusted quoted prices in active markets for identical assets or liabilities;
		Level 2	quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and
		Level 3	unobservable inputs for the asset or liability.
	At March 31, 2015 and 2014, we had no assets or liabilities that were valued at fair value on a recurring basis.
	The fair value of indefinite-lived assets or long-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with the Company’s impairment test. There was no impairment of intangible assets or long-lived assets during the three months ended March 31, 2015 and 2014.
Revenue Recognition	Revenue Recognition
	We recognize revenue on arrangements in accordance with ASC 605, Revenue Recognition. We recognize revenue only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably assured.
	Our OTC and prescription prenatal vitamin products are generally variations of the same product with slight modifications in formulation and marketing. The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers of our OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products pay for the product via third-party payers. Both OTC and prescription prenatal vitamin products share the same marketing support team utilizing similar marketing techniques.
	Over-the-Counter Products
	We generate OTC revenue from product sales primarily to retail consumers. We recognize revenue from product sales upon shipment, when the rights of ownership and risk of loss have passed to the consumer. We include outbound shipping and handling fees in sales and bill them upon shipment. We include shipping expenses in cost of sales. A majority of our customers pay for our products with credit cards, and we usually receive the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to sales. We provide an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce customers. We recognize our revenue from OTC sales, net of returns, sales discounts, and eCommerce fees.
	Prescription Products
	We sell our name brand and generic prescription products primarily through drug wholesalers and retail pharmacies. We recognize revenue from prescription product sales, net of sales discounts, chargebacks, and rebates.
	We accept returns of unsalable product from customers within a return period of six months prior to and up to 12 months following product expiration. Our prescription products currently have a shelf life of 24 months from the date of manufacture. As of January 1, 2015, we started estimating returns based on historical return rates and record actual product returns against this reserve as received.
	We maintain various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. The consumer rebate program is designed to enable the end user to return a coupon to us. If the coupon qualifies, we send a rebate check to the end user. We estimate the allowance for consumer rebates based on our experience and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis.
Research and Development Expenses	Research and Development Expenses
	Research and development, or R&D, expenses include internal R&D activities, services of external contract research organizations, or CROs, costs of their clinical research sites, and other activities. Internal R&D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. Advance payments to be expensed in future research and development activities were $995,144 and $1,175,082, at March 31, 2015 and December 31, 2014, respectively. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting and legal counsel. The activities undertaken by our regulatory consultants that were classified as research and development expenses include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. Legal activities that were classified as research and development expenses related to designing experiments to generate data for patents and to further the formulation development process for our pipeline technologies. Outside legal counsel also provided professional research regarding the legal landscape of potential patents. These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal R&D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&D activities when the activity has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. As of March 31, 2015, we classified $651,567 of the accrued clinical study costs as Accrued Expense related to the costs that will be paid at the completion of one of our clinical trials. Accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become known.
Segment Reporting	Segment Reporting
	We are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by a single management team that reports to the President of our Company. We do not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.

INVENTORY_Tables

INVENTORY (Tables)	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consists of the following:
		March 31,   2015		December 31,   2014
	Finished product	$	789,174	$	874,294
	Raw material		170,014		155,341
	Deferred costs		—		152,478
	TOTAL INVENTORY	$	959,188	$	1,182,113

OTHER_CURRENT_ASSETS_Tables

OTHER CURRENT ASSETS (Tables)	3 Months Ended
	Mar. 31, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of other current assets	Other current assets consist of the following:
		March 31,   2015		December 31,   2014
	Prepaid consulting	$	411,864	$	411,864
	Other receivables-related party (Note 13)		249,981		249,981
	Prepaid insurance		237,867		394,878
	Prepaid research and development costs		222,526		299,498
	Prepaid vendor deposits		171,374		—
	Other prepaid costs		152,383		181,186
	TOTAL OTHER CURRENT ASSETS	$	1,445,995	$	1,537,407

FIXED_ASSETS_Tables

FIXED ASSETS (Tables)	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Schedule of fixed assets	Fixed assets consist of the following:
		March 31,   2015			31-Dec-14
	Equipment	$	132,150		$	132,150
	Furniture and fixtures		53,895			53,895
			186,045			186,045
	Accumulated depreciation		(129,633	)		(122,752	)
	TOTAL FIXED ASSETS	$	56,412		$	63,293

PREPAID_EXPENSE_Tables

PREPAID EXPENSE (Tables)	3 Months Ended
	Mar. 31, 2015
Prepaid Expense and Other Assets [Abstract]
Schedule of prepaid expense	Prepaid expense consists of the following:
		March 31,   2015		31-Dec-14
	Prepaid manufacturing costs	$	899,000	$	899,000
	Prepaid research and development costs		360,754		463,720
	Accreted prepaid costs		74,385		64,543
	TOTAL PREPAID EXPENSE	$	1,334,139	$	1,427,263

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets	The following table sets forth the gross carrying amount and accumulated amortization of our intangible assets as of March 31, 2015 and December 31, 2014:
			31-Mar-15
			Gross Carrying Amount				Accumulated Amortization			Net		Weighted- Average Amortization Period (yrs.)
										Amount
	Amortizing intangible assets:
	OPERA® software patent		$	31,951			$	(2,995	)	$	28,956		14.5
	Development costs of corporate website			91,743				(91,743	)		—		n/a
	Approved hormone therapy drug candidate patents			439,184				(25,593	)		413,591		17.75
	Non-amortizing intangible assets:
	Hormone therapy drug candidate patents (pending)			691,465				—			691,465		n/a
	Multiple trademarks for vitamins/supplements			124,738				—			124,738		n/a
	Total		$	1,379,081			$	(120,331	)	$	1,258,750
			31-Dec-14
			Gross Carrying Amount				Accumulated Amortization			Net		Weighted- Average Amortization Period (yrs.)
										Amount
	Amortizing intangible assets:
	OPERA® software patent		$	31,951			$	(2,496	)	$	29,455		14.75
	Development costs of corporate website			91,743				(91,743	)		—		n/a
	Approved hormone therapy drug candidate patents			439,184				(19,401	)		419,783		18
	Non-amortizing intangible assets:
	Hormone therapy drug candidate patents (pending)			675,982				—			675,982		n/a
	Multiple trademarks for vitamins/supplements			103,368				—			103,368		n/a
	Total		$	1,342,228			$	(113,640	)	$	1,228,588
Schedule of estimated amortization expense	Estimated amortization expense for the next five years is as follows:
	Year Ending				Estimated
	December 31,				Amortization
		2015 (9 months)			$	20,074
		2016			$	26,765
		2017			$	26,765
		2018			$	26,765
		2019			$	26,765

OTHER_CURRENT_LIABILITIES_Tabl

OTHER CURRENT LIABILITIES (Tables)	3 Months Ended
	Mar. 31, 2015
Other Liabilities Disclosure [Abstract]
Schedule of other current liabilities	Other current liabilities consist of the following:
			March 31,   2015		31-Dec-14
	Accrued clinical trial costs		$	2,672,962	$	1,706,542
	Accrued payroll, bonuses and commission costs			900,662		814,205
	Accrued vacation costs			429,740		442,430
	Accrued legal and accounting expense			114,760		276,470
	Other accrued expenses(1)			312,181		185,965
	Allowance for wholesale distributor fees			121,469		160,503
	Accrued royalties			53,415		72,710
	Allowance for coupons and returns			184,521		90,446
	Accrued rent			89,742		91,368
	TOTAL OTHER CURRENT LIABILITIES		$	4,879,452	$	3,840,639
	____________
	-1	In June 2008, we declared and paid a special dividend of $0.40 per share of our Common Stock to all stockholders of record as of June 10, 2008, of which $41,359 remained unclaimed by certain shareholders at March 31, 2015 and December 31, 2014.

NET_LOSS_PER_SHARE_Tables

NET LOSS PER SHARE (Tables)	3 Months Ended
	Mar. 31, 2015
Net Loss Per Share Tables
Schedule of potentially dilutive securities	The table below presents the potentially dilutive securities that would have been included in our calculation of diluted net loss per share allocable to common stockholders if they were not antidilutive for the periods presented.
		Three months ended
		31-Mar-15		31-Mar-14
	Stock options		17,586,109		16,511,006
	Warrants		13,002,431		14,293,499
	Restricted stock units		—		50,000
			30,588,540		30,854,505

STOCKHOLDERS_EQUITY_Tables

STOCKHOLDERS' EQUITY (Tables)	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Schedule of assumptions used in the Black-Scholes Model of stock options	The assumptions used in the Black-Scholes Model during the three months ended March 31, 2015 and 2014 are set forth in the table below.
		Three Months			Three Months
		Ended			Ended
		March 31,			March 31,
		2015			2014
	Risk-free interest rate		1.47	%		1.70-1.75	%
	Volatility		58.78-62.59	%		69.15-70.76	%
	Term (in years)		5.27-6.25			5.5-6.25
	Dividend yield		0	%		0	%
Schedule of option activity	A summary of activity under the 2009 and 2012 Plans and related information follows:
		Number of Shares Underlying Stock			Weighted Average Exercise Price			Weighted   Average   Remaining   Contractual Life in Years		Aggregate Intrinsic Value
		Options
	Balance at December 31, 2014		16,792,443		$	1.88			6.92	$	43,996,311
	Granted		919,500		$	5.92
	Exercised		(11,250	)	$	0.64
	Cancelled		(114,584	)	$	2.82
	Balance at March 31, 2015		17,586,109		$	2.09			6.53	$	69,714,593
	Vested and Exercisable at		13,701,873		$	1.5			5.89	$	62,312,047
	31-Mar-15

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	3 Months Ended
	Mar. 31, 2015
Commitments And Contingencies Tables
Schedule of future minimum rental payments	As of March 31, 2015, future minimum rental payments are as follows:
	Years Ending December 31,
		2015 (9 months)	$	362,350
		2016		493,790
		2017		507,087
		2018		388,976
		Total minimum lease payments		1,752,203
		Non-cancellable sub-lease income		(—)
		Net minimum lease payments	$	1,752,203

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Advance payments for future research and development activities	$995,144	$1,175,082
Accrued Expense-LT	$651,567

INVENTORY_Details

INVENTORY (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Inventory
Finished product	$789,174	$874,294
Raw material	170,014	155,341
Deferred costs		152,478
TOTAL INVENTORY	$959,188	$1,182,113

OTHER_CURRENT_ASSETS_Details

OTHER CURRENT ASSETS (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Other Current Assets
Prepaid consulting	$411,864	$411,864
Other receivables-related party (Note 13)	249,981	249,981
Prepaid insurance	237,867	394,878
Prepaid research and development costs	222,526	299,498
Prepaid vendor deposits	171,374
Other prepaid costs	152,383	181,186
TOTAL OTHER CURRENT ASSETS	$1,445,995	$1,537,407

FIXED_ASSETS_Details_Narrative

FIXED ASSETS (Details Narrative) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Property, Plant and Equipment [Abstract]
Depreciation Expense	$6,881	$7,122

FIXED_ASSETS_Details

FIXED ASSETS (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Fixed assets, gross	$186,045	$186,045
Accumulated depreciation	-129,633	-122,752
TOTAL FIXED ASSETS	56,412	63,293
Equipment [Member]
Fixed assets, gross	132,150	132,150
Furniture and Fixtures [Member]
Fixed assets, gross	$53,895	$53,895

PREPAID_EXPENSE_Details

PREPAID EXPENSE (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Other Assets
Prepaid manufacturing costs	$899,000	$899,000
Prepaid research and development costs	360,754	463,720
Accreted prepaid costs	74,385	64,543
TOTAL PREPAID EXPENSE	$1,334,139	$1,427,263

INTANGIBLE_ASSETS_Details_Narr

INTANGIBLE ASSETS (Details Narrative) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Amortization expense	$6,691	$5,946
Development costs for corporate website [Member]
Amortization period	36 months
OPERA software patent [Member]
Amortization period	15 years
Average enforecable life	20 years
Approved Hormone Therapy Drug Candidate Patents [Member]
Amortization period	18 years

INTANGIBLE_ASSETS_Details

INTANGIBLE ASSETS (Details ) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets
Accumulated Amortization	($120,331)	($113,640)
Indefinite-Lived Intangible Assets
Gross Carrying Amount	1,379,081	1,342,228
Net Amount	1,258,750	1,228,588
Hormone therapy drug candidate patents - Pending [Member]
Indefinite-Lived Intangible Assets
Gross Carrying Amount	691,465	675,982
Net Amount	691,465	675,982
Multiple trademarks for vitamins/supplements [Member]
Indefinite-Lived Intangible Assets
Gross Carrying Amount	124,738	103,368
Net Amount	124,738	103,368
OPERA software patent [Member]
Finite-Lived Intangible Assets
Gross Carrying Amount	31,951	31,951
Accumulated Amortization	-2,995	-2,496
Net Amount	28,956	29,455
Weighted Average Amortization Period	14 years 6 months	14 years 9 months
Development costs for corporate website [Member]
Finite-Lived Intangible Assets
Gross Carrying Amount	91,743	91,743
Accumulated Amortization	-91,743	-91,743
Net Amount
Approved Hormone Therapy Drug Candidate Patents [Member]
Finite-Lived Intangible Assets
Gross Carrying Amount	439,184	439,184
Accumulated Amortization	-25,593	-19,401
Net Amount	$413,591	$419,783
Weighted Average Amortization Period		18 years
Non-Amortizing Intangible Assets [Member]
Finite-Lived Intangible Assets
Weighted Average Amortization Period	17 years 9 months

INTANGIBLE_ASSETS_Details_1

INTANGIBLE ASSETS (Details 1) (USD $)	Dec. 31, 2014
Estimated amortization expense for the year:
2015 (9 months)	$20,074
2016	26,765
2017	26,765
2018	26,765
2019	$26,765

OTHER_CURRENT_LIABILITIES_Deta

OTHER CURRENT LIABILITIES (Details Narrative) (USD $)	Mar. 31, 2015
Other Liabilities Disclosure [Abstract]
Date dividend declared	2008-06
Dividends Payable, amount per share	$0.40
Unclaimed dividends	$41,359

OTHER_CURRENT_LIABILITIES_Deta1

OTHER CURRENT LIABILITIES (Details) (USD $)	Mar. 31, 2015		Dec. 31, 2014
Other Liabilities Disclosure [Abstract]
Accrued clinical trial costs	$2,672,962		$1,706,542
Accrued payroll, bonuses and commission costs	900,662		814,205
Accrued vacation costs	429,740		442,430
Accrued legal and accounting expense	114,760		276,470
Other accrued expenses	312,181	[1]	185,965	[1]
Allowance for wholesale distributor fees	121,469		160,503
Accrued royalties	53,415		72,710
Allowance for coupons and returns	184,521		90,446
Accrued rent	89,742		91,368
TOTAL OTHER CURRENT LIABILITIES	$4,879,452		$3,840,639
[1]	In June 2008, we declared and paid a special dividend of $0.40 per share of our Common Stock to all stockholders of record as of June 10, 2008, of which $41,359 remained unclaimed by certain shareholders at March 31, 2015 and December 31, 2014.

NET_LOSS_PER_SHARE_Details

NET LOSS PER SHARE (Details)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from earnings per share calculation	30,588,540	30,854,505
Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from earnings per share calculation	17,586,109	16,511,006
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from earnings per share calculation	13,002,431	14,293,499
Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from earnings per share calculation		50,000

STOCKHOLDERS_EQUITY_Details_Na

STOCKHOLDERS' EQUITY (Details Narrative) (USD $)	3 Months Ended		0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Feb. 10, 2015	Dec. 31, 2014
Preferred stock, shares authorized	10,000,000			10,000,000
Preferred stock, par value (in dollars per share)	$0.00			$0.00
Common stock, shares authorized	250,000,000			250,000,000
Common stock, shares issued	172,651,036			156,097,019
Common stock, shares outstanding	172,651,036			156,097,019
Numbers of options to purchase shares of common stock	11,250	90,303
Numbers of portions shares issued for exercise of options, shares		88,736
Options to purchase shares of common stock, value	$7,208	$40,055
Numbers of options to purchase shares of common stock using cashless exercise feature		1,567
Numbers of options to purchase shares of common stock cancelled using cashless exercise feature		1,433
Number of shares issued in exercise of warrants	925,485
Amount of shares issued in exercise of warrants	358,400
Cowen and Company, LLC (Underwriters) [Member]
Number of shares issued during the period			13,580,246
Share price (in dollars per share)			$4.05
Number of shares issued during the period,value			$59,100,000
Numbers of options to purchase shares of common stock			2,037,036

STOCKHOLDERS_EQUITY_Details_Na1

STOCKHOLDERS' EQUITY (Details Narrative 1) (USD $)	3 Months Ended	1 Months Ended	0 Months Ended		3 Months Ended	1 Months Ended
	Mar. 31, 2015	31-May-13	Jun. 30, 2013	11-May-13	Mar. 31, 2014	Jan. 31, 2013	Dec. 31, 2014
Warrants:
Warrants outstanding	$13,002,431
Weighted-average contractual remaining life	2 years 6 months
Prepaid expense-long term	1,334,139						1,427,263
Sancilio and Company Warrants [Member]
Warrants:
Exercise price of warrants (in dollars per share)		$2.01
Unamortized costs of warrants	773,000
Number of shares purchased		850,000
Number of shares purchased forfeit		833,000
Sancilio & Company Warrants 1st Installments [Member]
Warrants:
Number of shares purchased				283,333
Vesting date of warrants				30-Jun-13
Fair value of warrants			405,066
Expected term			5 years
Volatility rate			45.89%
Risk free rate			1.12%
Dividend yield			0.00%
Valuation method of warrants			Black-Scholes Model
Non-cash compensation recongised			405,066
Sancilio and Company Warrants 2nd Installments [Member]
Warrants:
Number of shares purchased			283,333
Fair value of warrants			462,196
Expected term			5 years
Volatility rate			45.84%
Risk free rate			1.41%
Dividend yield			0.00%
Non-cash compensation recongised	38,517				38,517
Prepaid expense-short term	154,068
Prepaid expense-long term	38,509
Sancilio and Company Warrants 3rd Installments [Member]
Warrants:
Number of shares purchased	283,334
Multiple Advance Revolving Credit Note (Plato Warrant) [Member]
Warrants:
Exercise price of warrants (in dollars per share)						$3.20
Number of shares purchased						1,250,000
Expiration date of warrants						31-Jan-19
Vesting date of warrants						31-Oct-13
Fair value of warrants						1,711,956
Expected term						6 years
Volatility rate						44.29%
Risk free rate						0.88%
Dividend yield						0.00%
Amortization deferred financing costs	$0				$260,027
Minimum [Member]
Warrants:
Exercise price of warrants (in dollars per share)	$0.24
Maximum [Member]
Warrants:
Exercise price of warrants (in dollars per share)	$3.20
Weighted Average [Member]
Warrants:
Exercise price of warrants (in dollars per share)	$1.92

STOCKHOLDERS_EQUITY_Details_Na2

STOCKHOLDERS' EQUITY (Details Narrative 2) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Numbers of options oustanding	17,586,109		16,792,443
Option exercise prices (in dollars per shares)	$2.09		$1.88
Share-based compensation expense	$728,426	$1,006,025
Total unrecognized estimated compensation expense	$7,209,000
Recognized weighted-average period	1 year 215 days
Minimum [Member]
Option exercise prices (in dollars per shares)	$0.10
Maximum [Member]
Option exercise prices (in dollars per shares)	$5.92
2009 Long Term Incentive Compensation Plan [Member]
Description of plan	To provide financial incentives to employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created shareholder value by providing them stock options and other stock and cash incentives, or the Awards.
Number of shares authorized for issuance			25,000,000
Number of shares issued	15,617,635
2012 Stock Incentive Plan [Member]
Description of plan	Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company.
Number of shares authorized for issuance			10,000,000
Number of shares issued	1,968,474

STOCKHOLDERS_EQUITY_Details

STOCKHOLDERS' EQUITY (Details) (Stock Options [Member])	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.47%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate		1.70%
Expected Volatility	58.78%	69.15%
Expected term	5 years 3 months 7 days	5 years 6 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate		1.75%
Expected Volatility	62.59%	70.76%
Expected term	6 years 3 months	6 years 3 months

STOCKHOLDERS_EQUITY_Details_1

STOCKHOLDERS' EQUITY (Details 1) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Number Options
Options outstanding, beginning	16,792,443
Options Granted	919,500
Options Exercised	-11,250	-90,303
Options Cancelled	-114,584
Options outstanding, ending	17,586,109
Vested and exercisable	13,701,873
Weighted Average Exercise Price
Options outstanding, beginning	$1.88
Granted	$5.92
Exercised	$0.64
Cancelled	$2.82
Options outstanding, ending	$2.09
Vested and exercisable	$1.50
Weighted Average Remaining Contractual Life
Options outstanding, beginning	6 years 11 months 12 days
Options outstanding, ending	6 years 6 months 10 days
Vested and exercisable	5 years 10 months 20 days
Aggregate Intrinsic Value
Options outstanding, beginning	$43,996,311
Options outstanding, ending	69,714,593
Vested and exercisable	$62,312,047

RELATED_PARTIES_Details_Narrat

RELATED PARTIES (Details Narrative) (Pernix Therapeutics LLC [Member], USD $)	Mar. 30, 2015	Dec. 31, 2014
Pernix Therapeutics LLC [Member]
Receivables- legal fee reimbursement	$249,981	$249,981
Payable - related party	$46,000	$46,000

BUSINESS_CONCENTRATIONS_Detail

BUSINESS CONCENTRATIONS (Details Narrative) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Concentration Risk [Line Items]
Revenues	$4,475,049	$2,830,533
Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration Risk	95.00%	84.00%
Customer Concentration Risk [Member] | Sales Revenue [Member]
Concentration Risk [Line Items]
Concentration Risk	10.00%	10.00%
Deferred revenue [Member]
Concentration Risk [Line Items]
Concentration Risk	70.40%	81.75%
Customer A [Member] | Sales Revenue [Member]
Concentration Risk [Line Items]
Revenues	1,416,127	918,018
Customer B [Member] | Sales Revenue [Member]
Concentration Risk [Line Items]
Revenues	626,731	0
Customer C [Member] | Sales Revenue [Member]
Concentration Risk [Line Items]
Revenues	543,447	585,376
Customer D [Member] | Sales Revenue [Member]
Concentration Risk [Line Items]
Revenues	$386,909	$562,484

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Details Narrative) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Non-cancelable operating lease term	63 months
Monthly Base rent of leases	$30,149
Future minimum lease payments over life of lease	1,899,414
Rental Expense	90,448	90,448
Rental income		17,980
Monthly Base rent of additional leases agreement	9,367
Future minimum lease payments over life of additional leases agreement	$393,429

COMMITMENTS_AND_CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	Mar. 31, 2015
Future minimum rental payments, year ending December 31,
2015	$362,350
2016	493,790
2017	507,087
2018	388,976
Total minimum lease payments	1,752,203
Non-cancellable sub-lease income
Net minimum lease payments	$1,752,203